Nancy S. Lurker
Net Worth

Last updated:

What is Nancy S. Lurker net worth?

The estimated net worth of Ms. Nancy S. Lurker is at least $11,386,139 as of 10 Jul 2024. She owns shares worth $1,495,269 as insider, has earned $1,490,870 from insider trading and has received compensation worth at least $8,400,000 in EyePoint Pharmaceuticals, Inc..

What is the salary of Nancy S. Lurker?

Ms. Nancy S. Lurker salary is $1,050,000 per year as Pres, Chief Executive Officer & Director in EyePoint Pharmaceuticals, Inc..

How old is Nancy S. Lurker?

Ms. Nancy S. Lurker is 68 years old, born in 1957.

What stocks does Nancy S. Lurker currently own?

As insider, Ms. Nancy S. Lurker owns shares in one company:

Company Title Shares Price per share Total value
EyePoint Pharmaceuticals, Inc. (EYPT) Pres, Chief Executive Officer & Director 135,441 $11.04 $1,495,269

What does EyePoint Pharmaceuticals, Inc. do?

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT logo
EYPT
EyePoint Pharmaceuticals, Inc.
$11.04

Nancy S. Lurker insider trading

EyePoint Pharmaceuticals, Inc.

Ms. Nancy S. Lurker has made 4 insider trades between 2017-2024, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 137,174 units of EYPT stock on 21 Feb 2020. As of 10 Jul 2024 she still owns at least 135,441 units of EYPT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 11,111 N/A N/A
Option
Restricted Stock Units 11,111 N/A N/A
Option
Restricted Stock Units 20,000 N/A N/A
Option
Common Stock 17,534 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Restricted Stock Units 17,534 N/A N/A
Sale
Common Stock 29,956 $24.98 $748,241
Sale
Common Stock 5,044 $24.97 $125,949
Option
Common Stock 75,133 N/A N/A
Option
Restricted Stock Units 75,133 N/A N/A
Sale
Common Stock 20,000 $20.76 $415,200
Option
Common Stock 20,000 N/A N/A
Option
Restricted Stock Units 17,533 N/A N/A
Option
Restricted Stock Units 20,000 N/A N/A
Option
Common Stock 17,533 N/A N/A
Option
Restricted Stock Units 12,466 N/A N/A
Option
Common Stock 12,466 N/A N/A
Option
Common Stock 13,717 N/A N/A
Option
Restricted Stock Units 13,717 N/A N/A
Option
Restricted Stock Units 17,533 N/A N/A
Option
Common Stock 17,533 N/A N/A
Sale
Common Stock 10,000 $20.15 $201,480
Option
Restricted Stock Units 4,500 N/A N/A
Option
Common Stock 4,500 N/A N/A
Option
Common Stock 12,467 N/A N/A
Option
Restricted Stock Units 12,467 N/A N/A
Option
Restricted Stock Units 13,717 N/A N/A
Option
Common Stock 13,717 N/A N/A
Option
Restricted Stock Units 124,667 N/A N/A
Option
Common Stock 124,667 N/A N/A
Option
Restricted Stock Units 40,000 N/A N/A
Option
Common Stock 40,000 N/A N/A
Option
Common Stock 45,000 N/A N/A
Option
Restricted Stock Units 45,000 N/A N/A
Purchase
Common Stock 98,000 $1.06 $104,076
Option
Common Stock 137,174 N/A N/A
Option
Restricted Stock Units 137,174 N/A N/A
Option
Restricted Stock Units 40,000 N/A N/A
Option
Common Stock 40,000 N/A N/A
Option
Common Stock 45,000 N/A N/A
Option
Restricted Stock Units 45,000 N/A N/A
Purchase
Common Stock 28,500 $1.76 $50,246
Option
Restricted Stock Units 40,000 N/A N/A
Option
Common Stock 40,000 N/A N/A
Purchase
Common Stock 56,700 $1.76 $99,962

EyePoint Pharmaceuticals key executives

EyePoint Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: